Shares of Solventum Co. (NYSE:SOLV - Get Free Report) have been given an average rating of "Hold" by the eleven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $68.29.
Several research firms recently commented on SOLV. Mizuho started coverage on Solventum in a research note on Wednesday, December 4th. They set a "neutral" rating and a $70.00 target price for the company. Stifel Nicolaus initiated coverage on Solventum in a report on Tuesday, October 8th. They set a "buy" rating and a $82.00 price target on the stock. Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a research note on Friday, November 8th. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They set a "peer perform" rating on the stock. Finally, Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a report on Monday, November 11th.
Get Our Latest Analysis on SOLV
Solventum Stock Performance
SOLV traded down $1.77 during trading on Friday, reaching $67.19. 1,166,319 shares of the stock traded hands, compared to its average volume of 1,175,003. The stock's 50-day moving average is $69.42 and its 200 day moving average is $64.69. Solventum has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.
Institutional Trading of Solventum
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SOLV. Hollencrest Capital Management bought a new position in shares of Solventum during the second quarter valued at about $25,000. Modus Advisors LLC bought a new position in shares of Solventum during the 4th quarter worth approximately $25,000. Copeland Capital Management LLC purchased a new position in shares of Solventum in the 3rd quarter worth approximately $26,000. Mather Group LLC. purchased a new position in shares of Solventum in the 3rd quarter worth approximately $27,000. Finally, Studio Investment Management LLC bought a new position in shares of Solventum in the second quarter valued at approximately $29,000.
About Solventum
(
Get Free ReportSolventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Articles
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
